Tag: sickle cell disease

Latest articles

Bristol-Myers Squibb-Pfizer Alliance announces results from Phase 4 AUGUSTUS trial.

AUGUSTUS trial demonstrates favourable safety results

The Bristol-Myers Squibb-Pfizer Alliance has announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis ® (apixaban) versus vitamin K antagonists (VKAs) in patients...
Praluent gets European Commission approval in certain cardiovascular patients.

EC approves Praluent®to reduce risk in ASCVD patients

The European Commission (EC) has approved a new indication for Praluent® (alirocumab), to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease...
Women meeting at a table: Pharma and women's health

Pharma and women’s health partnerships

The Primary Care Women’s Health Forum presents many opportunities for partnerships that improve women’s health. The Primary Care Women’s Health Forum (PCWHF) was originally created...

Popular articles

Pf Awards 2019 logo

Pharma talent on show at Pf Awards 2019

The biggest names in the pharmaceutical industry came together at the Royal Lancaster London on the evening of 14 March. The largest pharmaceutical sales...
Smart phone image: Digital partnerships in pharma

Digital partnerships in pharma and the NHS

Can pharma and the NHS equal the fast pace of change necessary to fully embrace technological innovation? Over the last few years, slowly but surely,...
Bristol-Myers Squibb-Pfizer Alliance announces results from Phase 4 AUGUSTUS trial.

AUGUSTUS trial demonstrates favourable safety results

The Bristol-Myers Squibb-Pfizer Alliance has announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis ® (apixaban) versus vitamin K antagonists (VKAs) in patients...
pain relief patch released by nurofen

Nurofen launches a 24 hour ibuprofen pain relief patch

Nurofen announces the launch of the UK’s only 24 hour clinically proven pain relief patch containing ibuprofen.  Despite body pain being among the most commonly...

Market Access in practice: do you have a strategy?

This article is a little old... but if you're interested in Market Access we have plenty of new content: July 2018 Market Access Special Edition...